Share this: 
Studies will focus on priority populations underrepresented in HIV clinical research.
Two clinical trials have launched to examine a novel long-acting form of HIV pre-exposure prophylaxis (PrEP) in cisgender women and people who inject drugs. The mid-stage studies …